BridgeMD
A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination with Obinutuzumab, Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
EU CTIS ID: 2023-505625-14-00
What this study is testing
To determine: the maximal tolerated dose or optimal biologic dose and dose-limiting toxicity of glofitamab as single agent and in combination with obinutuzumab following Gpt in patients with r/r NHL a recommended dose and schedule of glofitamab as single agent and in combination with obinutuzumab following Gpt To evaluate: The safety, tolerability, and pharmacokinetic (PK) of glofitamab as single agent and in combination with obinutuzumab following obinutuzumab pretreatment (Gpt) in patients with r/r (CD)20 + B-cell NHL The efficacy of glofitamab as single agent following Gpt in patients in patients with Diffuse large B-cell lymphoma, and in patients with r/r Follicular lymphoma (FL) measured by Independent Review Committee (IRC)-assessed complete response rate (CRR) according to Lugano 2014 Classification To evaluate the efficacy of glofitamab as single agent following Gpt and/or dGpt in R/R MCL patients by IRC-assessed CRR according to Lugano Classification
- Phase I and Phase II (Integrated)- First administration to humans
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient willing and able to comply with protocol-mandated hospitalizations upon administration of glofitamab and also all study-related procedures, in Part III, this includes completion of Patient-reported outcome
- For Parts I and II:Grades 1-3b FL; Marginal zone lymphoma; Mantle cell lymphoma; DLBCL; Primary mediastinal B-cell lymphoma; Richter’s transformation; and transformed FL (trFL) For Part III expansion cohorts: DLBCL cohort (r/r DLBCL, not otherwise specified [NOS]/high-grade B-cell lymphoma [HGBCL],PMBCL and trFL). Patients must have relapsed after or failed to respond to at least two prior systemic treatment regimens (including at least one prior regimen containing anthracycline, and at least one containing an anti CD20-directed therapy). cohort: R/R FL cohort: Grades 1-3a FL patients must have relapsed after or failed to respond to at least two prior lines of systemic therapy and must have received prior treatment with rituximab and alkylating agents
- For Part III expansion cohorts: Life expectancy (in the opinion of the Investigator) of >= 12 weeks
- Measurable disease, defined as at least one bi-dimensionally measurable nodal lesion, defined as >1.5 cm in its longest dimension, or at least one bi-dimensionally measurable extranodal lesion, defined as >1.0 cm in its longest dimension
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Adequate liver, hematological, and renal function
You likely can't join if
- Inability to comply with protocol mandated hospitalization and restrictions
- Patients with chronic lymphocytic leukemia (CLL), Burkitt lymphoma and lymphoplasmacytic lymphoma
- Patients with a known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
- Patients with acute bacterial, viral, or fungal infection at baseline, confirmed by a positive blood culture within 72 hours prior to Gpt infusion or by clinical judgment in the absence of a positive blood culture
- Patients with known active infection, or reactivation of a latent infection, whether bacterial, viral, fungal, mycobacterial, or other pathogens or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of dosing
- Pregnant, breast-feeding or intending to become pregnant during the study
The study team makes the final eligibility decision.
Where it's taking place
- United States
- New Zealand
- Taiwan
- Australia
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; New Zealand; Taiwan; Australia; Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.